Pyxis Oncology, Inc.
$1.7
▲
0.68%
2026-04-21 09:00:02
www.pyxisoncology.com
NMS: PYXS
Explore Pyxis Oncology, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$104.3 M
Current Price
$1.7
52W High / Low
$5.55 / $0.89
Stock P/E
—
Book Value
$0.85
Dividend Yield
—
ROCE
-119.93%
ROE
-91.44%
Face Value
—
EPS
$-1.28
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
56
Beta
1.42
Debt / Equity
34.96
Current Ratio
3.41
Quick Ratio
3.41
Forward P/E
-1.31
Price / Sales
7.71
Enterprise Value
$58.63 M
EV / EBITDA
-0.76
EV / Revenue
4.23
Rating
Strong Buy
Target Price
$6.88
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Ascentage Pharma Group Internat | $25.65 | — | $18.58 B | — | -25.48% | -1.55% | $95.35 / $36.5 | $0.52 |
| 2. | Palvella Therapeutics, Inc. | $129.33 | — | $1.85 B | — | -80.06% | -92.1% | $151.18 / $20.2 | $2.26 |
| 3. | Ultragenyx Pharmaceutical Inc. | $25.06 | — | $2.39 B | — | -46.6% | -6.08% | $42.37 / $18.29 | $-0.83 |
| 4. | Annexon, Inc. | $6.43 | — | $1.05 B | — | -92.11% | -81.9% | $7.18 / $1.4 | $1.42 |
| 5. | Veru Inc. | $2.43 | — | $39 M | — | -161.13% | -60.25% | $7.4 / $2.06 | $2.31 |
| 6. | MindWalk Holdings Corp. | $1.27 | — | $59.32 M | — | -34.42% | -58.82% | $3.25 / $0.4 | $0.23 |
| 7. | Invivyd, Inc. | $1.68 | — | $492.08 M | — | -22.89% | -33.97% | $3.07 / $0.46 | $0.86 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 11.04 M | 0 M | 2.82 M | 0 M | 0 M | — |
| Operating Profit | -18.3 M | -23.46 M | -19.75 M | -22.91 M | -19.11 M | — |
| Net Profit | -18.11 M | -22 M | -18.35 M | -21.16 M | -35.57 M | — |
| EPS in Rs | -0.29 | -0.35 | -0.29 | -0.34 | -0.57 | -0.35 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 13.86 M | 16.15 M | 0 M | 0 M |
| Operating Profit | -84.42 M | -68.5 M | -82.2 M | -123.48 M |
| Net Profit | -79.62 M | -77.33 M | -73.79 M | -120.72 M |
| EPS in Rs | -1.27 | -1.23 | -1.17 | -1.92 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 91.52 M | 157.18 M | 173.73 M | 211.38 M |
| Total Liabilities | 38.11 M | 36.43 M | 48.02 M | 50.55 M |
| Equity | 53.41 M | 120.75 M | 125.7 M | 160.82 M |
| Current Assets | 72.11 M | 132.44 M | 124.6 M | 186.61 M |
| Current Liabilities | 21.13 M | 17.68 M | 25.76 M | 31.63 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -63.5 M | -57.67 M | -70.71 M | -89.33 M |
| Investing CF | 58.86 M | 8.15 M | -104.85 M | -6.4 M |
| Financing CF | 0.59 M | 59.33 M | 5.93 M | 0.18 M |
| Free CF | -63.51 M | -57.91 M | -77.44 M | -95.73 M |
| Capex | -0.01 M | -0.24 M | -6.73 M | -6.4 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -4.8% | 38.87% | — | — |
| Profit Margin % | -478.95% | — | — | — |
| Operating Margin % | -424.23% | — | — | — |
| Gross Margin % | 97.06% | — | — | — |
| EBITDA Margin % | -405.76% | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.